LEF1 and systemic lupus erythematosus: One limitation of this study is that treatment with the LEF-1 inhibitor triggered unexpected side effects during the development of the lupus model, leading to higher mortality in the treatment group and undermining the statistical differences between groups, the other limitation of this study is the absence of a Lef-1fl/flCd19cre/+ mouse model for more detailed research.